What to know about Moderna’s combined covid-flu vaccine on the horizon
Moderna’s combined coronavirus-influenza shot produced a higher immune response in older adults than separate vaccines for those viruses administered together, according to data the company released Monday.
The promising results from clinical trials, which have yet to be peer reviewed and published in a medical journal, could offer a new option to boost paltry uptake of updated coronavirus vaccines.
Moderna officials say the earliest that the combined vaccine could hit the market is fall 2025, pending regulatory approval.
Here’s what you need to know: